Plays Big Boards & Biotechs! Boardmark me as I am an honest, transparent, & well respected investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bingo! That is the study I was looking for. That data will come in late Dec. The approval for $EGLT should come by Dec 14th which is the 60-day window of Oct 14th PDUFA Extension.
$EGLT..not sure Roger. I will look into that. Did not realize they had data due in Q4. I was so focused on their approval from the FDA.
$EGLT..$7.82..agree with you 100%. Will look to buy a starter position soon. The upside is significant here with a broad label stating abuse deterrent. Any restricted label and the stock pops to $9-$9.50 then fades back again. The 40% short position should give it a pop and allow MM's to cover.
$NTRP..$28..the recent offering was at $.20. This stock will get some traction. Reminds me a lot of an early $TPIV or $AVXL. Both are stocks that sat and when they finally ran it was hard to catch them. I like that the financing is out of the way & in the clear.
$PLX..$.57..got as high as $.65 today. Absolutely flew on news that the delay from $HALO benefits their $PLX drug in Fabry Disease.
$CARA..$9.22.. Completes Enrollment of 8 week Multi-Dose Phase of Adaptive Trial of I.V. CR845 in CKD-Associated Pruritus. Top line data 1H 2017
$PFE..$31.84.. FDA Accepts the BLA for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review.
$CYTR.. Reports Statistically Significant Updated Results from Pivotal P3 Trial of Aldoxorubicin.
http://finance.yahoo.com/news/cytrx-reports-statistically-significant-updated-120000007.html
$CASC..$5.50 on the 1 for 6 R/S..looking to open lower post R/S than what it closed at yesterday which should be near $5.82 (.97 close)
$NOVN..$23.79..Announces Statistically Significant P2 Clinical Trial Results for SB206 for the treatment of genital warts.
http://finance.yahoo.com/news/novan-announces-statistically-significant-phase-110500805.html
$ARIA..$14.05..Announces FDA Full Approval And Label Update For Iclusig Based On Long-Term Efficacy And Safety Data From Phase 2 PACE Trial.
http://finance.yahoo.com/news/ariad-announces-fda-full-approval-123500695.html
Healthcare sector upcoming catalyst name w/in 10% of 52-week lows: $OPHT, $DMTX, $CEMP, $ITEK (H/T @redacre)
$GENE..$1.31.. Genetic Technologies enters exclusive worldwide agreement to develop colorectal cancer risk assesment test.
https://www.scribd.com/document/332594886/Genetic-Technolgies-to-Develop-Colorectal-Cancer-Risk-Assessment-Test (H/T @TradeHawk)
$ZSAN..$.80..I put in a bid but it jumped higher and moved higher on me. I was out so couldn't watch it but was hoping to grab a few cheapies in the Beginner Portfolio but didn't get it.
$NTRP..$.285..Bigger Capital Mgnmt & Michael Bigger were involved w/ the recent offering here. Some comment from him on Twitter which were requested from a few readers. Good color on what big investors are thinking. Thought it was interesting. Some are taking longer term approach & others trading it. I will take the $TPIV approach where I starter in the early $.30's waited a few months and it was over $1.50.
$EGLT..$7.00..Will have resolution in 4Q16 from FDA and be able to launch ARYMO in 1Q17. With 30% shares short could provide an interesting opportunity ahead.
$NTRP..$.27..no need to chase here. The offering has not been closed and is still active. Once it closes then it will move higher.
$PLX..$.48..another one with many catalysts by YE. Have to keep an eye on this one here.
New Economy Portfolio Alert..bought a stock at $.27 that has a defined catalyst in April 2017 for key data release point of Phase 2 data in Alzheimers Disease. The company did a 20m offering last week at $.20 and then did an additional 3.4m as it was oversubscribed. I think that this one has a solid move higher into the catalyst. Will be patient with this one. Will move higher in next 3 months as the space is red hot as companies look for any improvement over current therapies. Will be data from $AXON ($13.96) in 1Q2017 so there will be anticipation here. Company also looks to uplist to Nasdaq in 6 months (Mar/Apr 17)
Alert..bought $NTRP at $.275 in the New Economy Portfolio..Bought a solid 7% position and will look to add on pullback. I will be patient here. Have seen stocks like this really move into key data inflection points. Ph2B full alzheimers data readout available April 2017. Company has cash w/ recent financing and 30m EV.
Disclaimer: http://bit.ly/OlN9DB
$NTRP Corp Presentation Oct 2016
http://bit.ly/NTRPCorpPresentation
Statement from Neurotrope today:
http://www.otcmarkets.com/stock/NTRP/news?id=145616
$NTRP...Neurotrope raises $20M, set to finish PhII Alzheimer’s test: http://ow.ly/4SyR306j4LT
Interesting here from a Fund in on the offering:
http://biggercapital.squarespace.com/biggercapital-investment/2016/11/20/our-second-alzheimers-investment-neurotrope.html
$GTXI..$.85..only for 9mg. Clinical benefit endpoint includes Stable Disease. PR has no breakdown of CR/PR/SD. More data in Dec 2016 so very soon.
http://finance.yahoo.com/news/enobosarm-meets-pre-specified-primary-120000617.html
$RLYP FDA Approves sNDA for Veltassa® Removing Boxed Warning Regarding DDI
http://www.galenica.com/wAssetsGalenica/bin/en/medienmitteilungen/2016/20161128_en_mm_veltassa_us_label_fda.pdf
Nice bottom buster Nasdaq play! $IDXG
Biotech List..from myself & BioHunter w/ stocks to be looking at from Monday:
nice list: $PLX, $AGRX, $VYGR, $SCYX , $MDGN RT @SheffStation: Biotech Radar Watchers: $CASC $XXII $MACK $CTRV $NVLS $CERC $GTXI $HTBX
$CASC..$1.03..Closed today near LOD. Will be interesting here as the company will have new data presented at San Antonio Breast Cancer Conf. Played that one in Oct from $1.15 range to $1.70 so there is an opportunity there as well especially if it gets below $1.00.
$HTBX..Yes..pretty crazy volume at 8.4M but also a strong close at $1.87. Will be interesting to see if this continues into next week catalyst on Nov 30th.
bigcat2..definitely an FDA decision that is hard to predict. I think that under $1 is an opportunity. I am watching it closely for a possible re-entry from its run to $1.30-$1.50 level last time.
OT: Took a break from the board alerts during the election as stocks, biotechs in particular, were extremely volatile at that time. I will look to add a few plays for the board next week into December to end the year. Not sure what my I will do in 2017. Looking forward to a strong finish to the year!
$HTBX..$1.91..up 25% today on a solid move here. 6.7m in volume. Closed yesterday at $1.54. People seeing that a key catalyst is on tap for next week.
$HTBX Topline HS-410 Phase II Bladder Cancer Results at the Society of Urological Oncology Annual Meeting Nov.30.
https://globenewswire.com/news-release/2016/11/16/890483/0/en/Heat-Biologics-to-Present-Topline-HS-410-Phase-II-Bladder-Cancer-Results-at-the-Society-of-Urological-Oncology-Annual-Meeting.html
$IMMU..$3.55..thanks Kei. Moving today when everything else is getting spanked today.
$AMDA..$.73.. "The FDA did not clear its 510(k) premarket application to commercialize Valeo C+CsC" (@biorunup). Good information there. I would steer clear here.
$RXII..$2.17..watching here. Never had much success with that one here. Chart looking good the past few trading days.
$GTXI..$.78..looks great here today on that pullback! I think we see positive data soon here before San Antonio.
Mark..I have also been looking to buy & trade some of these cash rich stocks who market caps have yet to be realized. Keep them coming. They are plays that have loads of cash that are trading below cash w/ lots of upside. The fact that they are trading below cash with small debt protects against the downside. Balances out the portfolio from smaller-cap riskier plays.
$KITE..$51.34..Stifel Presentation today.
http://wsw.com/webcast/stifel5/kite/
$GTXI..$.89...Stifel Presentation today: Imminent Catalysts Ahead. Key Breast Cancer Catalyst in a few weeks (Dec 2016)
http://wsw.com/webcast/stifel5/gtxi/
Presentation by Dr. Beth Overmyer at Harvard
http://bit.ly/GTXIDrOvermyeronEnobosarm